CO2021003726A2 - Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto - Google Patents

Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto

Info

Publication number
CO2021003726A2
CO2021003726A2 CONC2021/0003726A CO2021003726A CO2021003726A2 CO 2021003726 A2 CO2021003726 A2 CO 2021003726A2 CO 2021003726 A CO2021003726 A CO 2021003726A CO 2021003726 A2 CO2021003726 A2 CO 2021003726A2
Authority
CO
Colombia
Prior art keywords
methods
diabetes
patients
statin
risk
Prior art date
Application number
CONC2021/0003726A
Other languages
English (en)
Spanish (es)
Inventor
Narendra Dhanraj Lalwani
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69591419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2021003726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CO2021003726A2 publication Critical patent/CO2021003726A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2021/0003726A 2018-08-24 2021-03-24 Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto CO2021003726A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US201862751404P 2018-10-26 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Publications (1)

Publication Number Publication Date
CO2021003726A2 true CO2021003726A2 (es) 2021-07-30

Family

ID=69591419

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003726A CO2021003726A2 (es) 2018-08-24 2021-03-24 Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto

Country Status (15)

Country Link
US (1) US20210322376A1 (cg-RX-API-DMAC7.html)
EP (1) EP3841105A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021534208A (cg-RX-API-DMAC7.html)
KR (1) KR20210079275A (cg-RX-API-DMAC7.html)
CN (1) CN113166195A (cg-RX-API-DMAC7.html)
AU (1) AU2019325705A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110346A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000444A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003726A2 (cg-RX-API-DMAC7.html)
IL (1) IL281016A (cg-RX-API-DMAC7.html)
MX (1) MX2021002090A (cg-RX-API-DMAC7.html)
PH (1) PH12021550656A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101717WA (cg-RX-API-DMAC7.html)
WO (1) WO2020041799A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
WO2020046836A1 (en) * 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901959A (en) * 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
MX2019009418A (es) * 2017-02-08 2019-10-02 Esperion Therapeutics Inc Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.

Also Published As

Publication number Publication date
CL2021000444A1 (es) 2021-07-02
SG11202101717WA (en) 2021-03-30
WO2020041799A1 (en) 2020-02-27
BR112021003265A2 (pt) 2021-05-18
KR20210079275A (ko) 2021-06-29
IL281016A (en) 2021-04-29
CA3110346A1 (en) 2020-02-27
EP3841105A4 (en) 2022-05-04
US20210322376A1 (en) 2021-10-21
JP2024081650A (ja) 2024-06-18
AU2019325705A1 (en) 2021-03-18
JP2021534208A (ja) 2021-12-09
MX2021002090A (es) 2021-04-28
CN113166195A (zh) 2021-07-23
EP3841105A1 (en) 2021-06-30
PH12021550656A1 (en) 2022-03-14

Similar Documents

Publication Publication Date Title
MX2023003942A (es) Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
UA122331C2 (uk) Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
BR112022007721A2 (pt) Método para o tratamento da demência
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
RU2016117729A (ru) Терапия рака путем таргетинга покоящихся раковых клеток
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
CO2017008395A2 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2022003610A (es) Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)